NuCress™ for Spinal Fusion

About NuShores Biosciences

NuShores Biosciences is developing the NuCress™ scaffold, a novel bone regeneration technology targeting large segmental bone defects (>2.5 cm) resulting from trauma, cancer, or warfare. The company holds an exclusive global license to patented intellectual property developed from over $15 million in grant-funded research at the University of Arkansas at Little Rock. While not yet FDA-cleared or commercially available, NuCress™ has demonstrated promising safety and efficacy in extensive preclinical animal studies across multiple species. NuShores operates as a pre-revenue, private entity aiming to address a significant unmet need in orthopedic, dental, and cranio-maxillofacial reconstruction.

Therapeutic Areas